Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

4(66.7%)

N/A

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 4(4)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07345624Phase 4Not Yet Recruiting

Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B

Role: collaborator

NCT07345611Phase 4Not Yet Recruiting

Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B

Role: collaborator

NCT05913362Not ApplicableUnknown

IVUS Guided PCI for CKD to Reduce CI-AKI

Role: collaborator

NCT04939441Phase 4Unknown

Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)

Role: collaborator

NCT04850950Phase 4Unknown

Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B

Role: collaborator

NCT04109183Phase 2Completed

A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV Treatment

Role: collaborator

All 6 trials loaded